Results continue to suggest urgent need for new therapies in MoCD Type A, with median survival of <4 years and rapid disease onset within the first month of life for most patients Continue to ...
Early administration of the drug Fosdenopterin/rcPMP improves the chances of survival of infants with MoCD type A and promotes the development of brain functions. The drug fosdenopterin/rcPMP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback